April 2025

Чи можна застосовувати DBT-C у роботі з дітьми-аутистами та їхніми сім’ями?

Dialectical Behavior Therapy for Children (DBT-C) is an empirically validated treatment that has been developed by Dr. Perepletchikova for children with severe emotional dysregulation and behavioral discontrol. Although empirical research is needed to evaluate its efficacy with children with Autism Spectrum Disorder, clinical observations support its use with autistic, subtly autistic, and sub-autistic neurotype children and their families.

Чи можна застосовувати DBT-C у роботі з дітьми-аутистами та їхніми сім’ями? Read More »

¿Es posible utilizarse la DBT-C con niños autistas y sus familias?

La Terapia Dialéctica Conductual para Niños (DBT-C) es una adaptación empíricamente fundamentada de la DBT, desarrollada por la Dra. Francheska Perepletchikova, orientada al tratamiento de niños con desregulación emocional significativa y dificultades conductuales. Si bien se requiere evidencia empírica más amplia para validar su eficacia específica en el contexto del Trastorno del Espectro Autista (TEA), la experiencia clínica acumulada respalda su aplicabilidad en niños autistas, sutilmente autistas y con neurotipos cercanos al espectro, así como en sus familias.

¿Es posible utilizarse la DBT-C con niños autistas y sus familias? Read More »

Can DBT-C be used with autistic children and their families?

Dialectical Behavior Therapy for Children (DBT-C) is an empirically validated treatment that has been developed by Dr. Perepletchikova for children with severe emotional dysregulation and behavioral discontrol. Although empirical research is needed to evaluate its efficacy with children with Autism Spectrum Disorder, clinical observations support its use with autistic, subtly autistic, and sub-autistic neurotype children and their families.

Can DBT-C be used with autistic children and their families? Read More »

Registration is open for 2025!

DBT and DBT-C workshops for parents and therapists are currently open for enrollment for 2025.